Roberto Buonaiuto: Findings on Trop-2 Expression and ADC Benefit in Metastatic Breast Cancer
Roberto Buonaiuto, Breast Medical Oncology Resident at the National Cancer Institute IRCCS Fondazione G. Pascale and Research Fellow at the Jules Bordet Institute, shared a post on X: “Just out […]
Read the full articleYou might also wanna read
TROP2 targeting reveals therapy-driven cell state dynamics in colorectal cancer
Nature, Published online: 01 July 2026; doi:10.1038/s41586-026-10705-2 TROP2 marks poor-prognosis colorectal cancer cells with fetal-like, t
Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy
Methylation-based ctDNA monitoring in 57 patients closely reflects outcomes in ER+, HER2- metastatic breast cancer during CDK4/6 inhibitor t
Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer
Conditions : Breast Cancer (Triple Negative Breast Cancer (TNBC)) Interventions : Other: Non interventional study Sponsors : Assistance Publ
Científicos financiados por los Institutos Nacionales de la Salud descubren pistas sobre las lesiones precancerosas y la biología tumoral
En nuevos estudios publicados por la Red del Atlas de Tumores Humanos (HTAN) del Instituto Nacional del Cáncer (NCI), se explora la función
Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC
Conditions : NSCLC; EGFR Activating Mutation; EGFR-TKI-resistant Non-Small Cell Lung Cancer; Trop2; PET/CT Imaging Interventions : Diagnosti
Molecular tumor boards show promise in bridging precision oncology's translation gap
Molecular tumor boards translate complex genomic data to more effectively inform personalized care, and a new meta-analysis shows they boost
plos.io·15d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.